News | Ultrasound Imaging | September 17, 2020

Ultrasound Guidance for Carpal Tunnel

Ultrasound-guided carpal tunnel release quickly improves hand function and reduces hand discomfort, making the procedure a safe, effective, and less invasive alternative to traditional open or endoscopic surgery

Ultrasound-guided carpal tunnel release quickly improves hand function and reduces hand discomfort, making the procedure a safe, effective, and less invasive alternative to traditional open or endoscopic surgery

Patients answered three questionnaires (Quick-Disabilities of the Arm, Shoulder, and Hand [QDASH] and two parts of the Boston Carpal Tunnel Syndrome Questionnaire: symptom severity [BCTSQ-SS] and functional status [BCTSQ-FS] scales) assessing the affected wrist's function and discomfort immediately pre-procedure, 2 weeks post-procedure, and at least one year post-procedure. Infographic courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

September 17, 2020 — According to ARRS' American Journal of Roentgenology (AJR), ultrasound-guided carpal tunnel release (UGCTR) quickly improves hand function and reduces hand discomfort, making UGCTR a safe, effective, and less invasive alternative to traditional open or endoscopic surgery.

Because ultrasound guidance allows carpal tunnel release to be performed with smaller incisions and quicker recovery, five researchers from Thomas Jefferson University Hospital in Philadelphia, Pa., set out to evaluate UGCTR's long-term efficacy in improving function and discomfort in patients with carpal tunnel syndrome.

Sixty-one UGCTR procedures performed in 46 patients (25 women and 21 men; mean age 60.6 years) with clinically diagnosed carpal tunnel syndrome were retrospectively reviewed. All procedures were performed under local anesthetic at an outpatient radiology office using the SX-One MicroKnife (Sonex Health).

As first AJR author Sarah I. Kamel explained: "Patients answered three questionnaires (Quick-Disabilities of the Arm, Shoulder, and Hand [QDASH] and two parts of the Boston Carpal Tunnel Syndrome Questionnaire: symptom severity [BCTSQ-SS] and functional status [BCTSQ-FS] scales) assessing the affected wrist's function and discomfort immediately pre-procedure, 2 weeks post-procedure, and at least one year post-procedure."

Median pre-procedure scores were 45.4 for QDASH, 3.2 for BCTSQ-SS, and 2.5 for BCTSQ-FS. Median 2 week post-procedure scores were 22.5 for QDASH, 1.7 for BCTSQ-SS, and 1.9 for BCTSQ-FS--all decreased (p < 0.001) from pre-procedure scores and surpassing reference standards for clinically important difference in scores.

Follow-up questionnaires were obtained for 90% (55/61) of wrists, a median of 1.7 years post-procedure, with further declines (p < 0.001) in median scores: 2.3 for QDASH, 1.2 for BCTSQ-SS, and 1.1 for BCTSQ-FS. At long-term follow-up, 96% (52/54) of wrists demonstrated lower QDASH, and 98% (53/54) lower BCTSQ (average of BCTSQ-SS and BCTSQ-FS), vs pre-procedure scores.

Although no immediate postoperative complications occurred, the authors of this AJR article detailed several response modifications for two patients who required surgery for complications experienced 8-10 days postoperatively (one for infection following injury and one for post-traumatic compartment syndrome).

"The procedure now includes more extensive preprocedural cleaning that extends to the forearm circumferentially prior to draping. A Tegaderm (3M Company, St. Paul, MN) is now placed at the distal third of the forearm to act as an additional sterile barrier at the edge of the sterile field. In addition, two passes of the ligament transection are performed routinely on all patients to potentially decrease the risk of remnant tissue that may contribute to incomplete release," Kamel et al. added.

For more information: www.arrs.org

Related Content

Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA)

56-Year-Old Woman With Benign Hemangioma: Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA) MR image shows lesion is homogeneously hyperintense compared with liver parenchyma.

News | Magnetic Resonance Imaging (MRI) | October 16, 2020
October 16, 2020 — 
Carestream Health will offer insights on technology, innovative new products and research in medical imaging through a new webinar series titled Carestream Talks. #RSNA20
News | Radiology Education | October 14, 2020
October 14, 2020 — Carestrea
A Butterfly Network point-of-care ultrasound (POCUS) system being used in Africa. The vendor wants to democratize ultrasound, making it less expensive and available everywhere, including rural areas and the developing world.

A Butterfly Network point-of-care ultrasound (POCUS) system being used in Africa. The vendor wants to democratize ultrasound, making it less expensive and available everywhere, including rural areas and the developing world.

Feature | Point-of-Care Ultrasound (POCUS) | October 08, 2020 | By Alan Stoddart
For all the changes in medicine there are some things that seem resolutely stable.
Butterfly Network Inc. is launching its next-generation Butterfly iQ+ point-of-care-ultrasound (POCUS) technology that can turn a smartphone into a diagnostic imaging system. It offers a new needle guidance app.

Butterfly Network Inc. is launching its next-generation Butterfly iQ+ point-of-care-ultrasound (POCUS) technology that can turn a smartphone into a diagnostic imaging system. It offers a new needle guidance app.

News | Point-of-Care Ultrasound (POCUS) | October 08, 2020
October 8, 2020 – Butterfly Network Inc.